Intrinsic activating properties of GP IIb/IIIa blockers

被引：28

作者：

Peter, K ^{[1
]}

Schwarz, M ^{[1
]}

Nordt, T ^{[1
]}

Bode, C ^{[1
]}

机构：

[1] Univ Freiburg, Dept Cardiol & Angiol, D-79106 Freiburg, Germany

来源：

THROMBOSIS RESEARCH | 2001年 / 103卷

关键词：

GP IIb/IIIa blockers; intrinsic activating property; thrombocytopenia; abciximab; tirofiban; eptifibatide;

D O I：

10.1016/S0049-3848(01)00300-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Potential intrinsic activating properties are probably the most controversially discussed issues with respect to GP IIb/IIIa blockers, especially since clinical trials with oral GP IIb/IIIa blockers revealed disappointing results. Based on the finding that currently clinically used GP IIb/IIIa blockers are ligand mimetics, experimental data are discussed, demonstrating an intrinsic activating effect of ligand mimetic GP IIb/IIIa blockers that potentially results in fibrinogen binding to alpha (IIb)beta (3) and in platelet aggregation. Furthermore, the inhibitory effect of aspirin on GP IIb/IIIa blocker-induced platelet aggregation is discussed as a clinically relevant finding. Finally, the potential association of GP IIb/IIIa blocker-induced thrombocytopenia with platelet activation is described. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：S21 / S27

页数：7

共 49 条

[1] Abciximab facilitates the rate and extent of thrombolysis - Results of the thrombolysis in myocardial infarction (TIMI) 14 trial [J].

Antman, EM ;

Giugliano, RP ;

Gibson, CM ;

McCabe, CH ;

Coussement, P ;

Kleiman, NS ;

Vahanian, A ;

Adgey, AAJ ;

Menown, I ;

Rupprecht, HJ ;

Van der Wieken, R ;

Ducas, J ;

Scherer, J ;

Anderson, K ;

Van de Werf, F ;

Braunwald, E .

CIRCULATION, 1999, 99 (21) :2720-2732

[2] Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb IIIa [J].

Bednar, B ;

Cook, JJ ;

Holahan, MA ;

Cunningham, ME ;

Jumes, PA ;

Bednar, RA ;

Hartman, GD ;

Gould, RJ .

BLOOD, 1999, 94 (02) :587-599

[3]

Berkowitz SD, 1997, CIRCULATION, V95, P809

[4] PLATELET GLYCOPROTEIN-IIB - CHROMOSOMAL LOCALIZATION AND TISSUE EXPRESSION [J].

BRAY, PF ;

ROSA, JP ;

JOHNSTON, GI ;

SHIU, DT ;

COOK, RG ;

LAU, C ;

KAN, YW ;

MCEVER, RP ;

SHUMAN, MA .

JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (06) :1812-1817

[5] Platelet integrin GPIIb/IIIa: Structure-function correlations. An update and lessons from other integrins [J].

Calvete, JJ .

PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1999, 222 (01) :29-38

[6] Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial [J].

Cannon, CP ;

McCabe, CH ;

Wilcox, RG ;

Langer, A ;

Caspi, A ;

Berink, P ;

Lopez-Sendon, J ;

Toman, J ;

Charlesworth, A ;

Anders, RJ ;

Alexander, JC ;

Skene, A ;

Braunwald, E .

CIRCULATION, 2000, 102 (02) :149-156

[7] A NEW MURINE MONOCLONAL-ANTIBODY REPORTS AN ACTIVATION-DEPENDENT CHANGE IN THE CONFORMATION AND OR MICROENVIRONMENT OF THE PLATELET GLYCOPROTEIN IIB/IIIA COMPLEX [J].

COLLER, BS .

JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (01) :101-108

[8] Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics [J].

Coller, BS .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1467-1471

[9] Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes [J].

Cox, D ;

Smith, R ;

Quinn, M ;

Theroux, P ;

Crean, P ;

Fitzgerald, DJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (05) :1514-1519

[10] LIGANDS ACTIVATE INTEGRIN ALPHA-IIB-BETA-3 (PLATELET GPIIB-IIIA) [J].

DU, XP ;

PLOW, EF ;

FRELINGER, AL ;

OTOOLE, TE ;

LOFTUS, JC ;

GINSBERG, MH .

CELL, 1991, 65 (03) :409-416

← 1 2 3 4 5 →